Hengrui Medicine : The upward trend is accelerating above the moving average. What do you think?
Hengrui Medicine has attracted great attention in the market. Hengrui Medicine has shown an accelerating upward trend above the bullish trend moving average. Especially in the past three trading days, it has shown the characteristics of continued heavy volume, continuous upward movement, and stock prices reaching new stage highs.
What kind of situation is this? How should we look at it? From a technical point of view,
reached a periodic low of 27.00 yuan at the end of April 2022, and then began to gradually advance. When he just started, there were five consecutive positive lines at the bottom.
This is a relatively iconic thing for Hengrui Medicine. That is to say, after the bottom is initially confirmed, it is obvious that the main market forces adopt a ladder method of small positive lines and small negative lines to promote the stock price.
formed a simple upward trend, and then gradually pushed up the stock price within a month and a half. Its stock price also rose from 27.00 yuan to 41.50 yuan. In this continuous and relatively stable upward trend,
's technical indicators have gradually adjusted to a long arrangement.
Now, he has effectively stood above the mid-term moving average of 120. From a medium to long-term perspective, based on the substantial rise in the previous two years, Hengrui Medicine's stock price has dropped from 116.87 yuan to around 27.00 yuan since early January 2021. The decline lasted for 15 months. During the decline, a relatively standard three-wave decline took place. Recently, after the bottom was confirmed, it is obvious that the main market forces have re-intervened and followed. The bottom of
gradually raised, and gradually stood on the mid-term and short-term moving averages.
Analyze the medium and long-term technical indicator MACD. After MACD reaches the bottom of and golden cross , the bottom volume can continue to amplify. This is relatively rare among large-cap stocks and among market leaders.
Hengrui Medicine’s total share capital is 6.380 billion, and its net assets per share are 5.68 yuan. The stock price is 41.17 yuan, and its turnover rate reached 2.22%.
Hengrui Pharmaceutical's fundamentals are relatively good. It has the concept of anti-cancer, immunotherapy , the concept of large-cap stocks, the concept of heavy fund positions, the concept of margin trading and securities lending, etc. Judging from his operating income, the operating income of his pharmaceutical manufacturing industry is 25.780 billion, accounting for 99.52% of the main business income.
Looking at the region of operating income, its domestic operating income is 25.163 billion yuan, accounting for 97.14% of its main business income. Sales revenue from foreign regions was 616 million yuan, accounting for 2.38% of the main business revenue.
It can also be seen from this that it is a pure manufacturing company, a large pharmaceutical manufacturing company, and its sales mainly come from domestic. Combined with its technical trend, the direction is relatively clear.
Due to the relatively lagging price increase of the pharmaceutical sector in this rebound, coupled with its relatively deep decline, it is the leader in the industry, its short-term technical indicators are relatively clear, and its trend direction is also relatively clear. It is still worthy of continuous observation and continuous tracking.
What do you think? The analysis of
is for reference only, please be cautious when investing.
